Zyprexa

(olanzapine)

ApprovedSmall molecule

Olanzapine is used to treat schizophrenia and bipolar disorder by helping to balance certain chemicals in the brain that affect mood and thinking. It can help reduce hallucinations, delusions, and mood swings.[2] Zyprexa is currently approved and in use across 47 indications[4].[1]

Zyprexa is one of 722 small molecule programs targeting Anorexia. It is currently in Approved.

Indications

316

Total Trials

Active Trials

721

Competitors

142

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

DexamethasoneRecruiting

Treatment Refractory SchizophreniaActive, not recruiting

Depressive DisorderActive, not recruiting

Migraine DisorderActive, not recruiting

PsychosisActive, not recruiting

Major Depressive DisorderActive, not recruiting

Drug-Induced DyskinesiaApproved

Opioid Use DisorderApproved

Body Weight GainApproved

Fish-Eye DiseaseApproved

DexamethasonePhase 3

Recruiting

Treatment Refractory SchizophreniaPreclinical

Active, not recruiting

Depressive DisorderApproved

Active, not recruiting

Migraine DisorderPreclinical

Active, not recruiting

PsychosisApproved

Active, not recruiting

Major Depressive DisorderApproved

Active, not recruiting

Drug-Induced DyskinesiaApproved

Approved

Opioid Use DisorderApproved

Approved

Body Weight GainApproved

Approved

Fish-Eye DiseaseApproved

Approved

Showing 10 of 44 indications

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Approved

5 2

Fludara

Sanofi

Phase 3

1 3

Oxycontin

PPurdue Pharma LP

Phase 3

1 4

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 5

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

4 6

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

1 7

Raphamin

MMateria Medica Holding

Phase 3

2 8

Lerodalcibep

LLIB Therapeutics LLC

Phase 3

7 9

Zvs101e

CChigenovo Co., Ltd

Phase 3

1 10

Rhtpo

SShandong University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Efficacy and Safety

NCT07482891

Q3 2027

Phase 3Recruiting

Dexamethasone

NCT07413809

Recruiting

Bipolar Disorder

NCT07263191

Q4 2027

Phase 3Recruiting

Vomiting

NCT06588413

Phase 3Recruiting

Cardiac Arrest

NCT05895838

Q1 2028

Phase 3Recruiting

Lung Cancer

NCT06338683

Clinical

Trials by Indication[1]

Schizophrenia51 trials

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

Completed·UUniversity of Massachusetts, Worcester·Phase 4·NCT00981526·66 enrolled

Metabolic Profile and Anthropometric Changes in Schizophrenia

Completed·—·N/A·NCT00534183·2,006 enrolled

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00337662·628 enrolled

Show 48 more trials

Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00088491·1,205 enrolled

Zyprexa and Task Engagement in Schizophrenia

Withdrawn·VVA Connecticut Healthcare System·Phase 3·NCT00440843

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

Completed·MMinerva Neurosciences·Phase 1·NCT06107803·17 enrolled

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

Completed·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT00053703·116 enrolled

Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 4·NCT01052389·300 enrolled

Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients

Completed·—·Phase 4·NCT01149577·25 enrolled

Cardio Risk of Acute Schizophrenia Olanzapine Duke

Withdrawn·—·Phase 4·NCT00672464

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00036088·530 enrolled

Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

Unknown status·TTianjin Medical University General Hospital·Phase 1·NCT03790085·2,700 enrolled

A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia

Completed·QQ.Mundewadi Ayurvedic Research & Charitable Trust·Phase 2·NCT00483964·200 enrolled

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00089869

Efficacy of Lu 31-130 in Patients With Schizophrenia

Completed· Lundbeck logo

Lundbeck·Phase 2·NCT00770744·93 enrolled

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

Completed·UUniversity of California, Los Angeles·Phase 4·NCT00183625·107 enrolled

Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00239109·112 enrolled

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01193166

A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06649214·654 enrolled

Exploratory Cognition Study of Sertindole in Patients With Schizophrenia

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT00759421·96 enrolled

D-serine Monotherapy for Schizophrenia

Completed·HHerzog Hospital·Phase 2·NCT00816894·18 enrolled

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

Completed·AAlkermes, Inc.·Phase 3·NCT02694328·561 enrolled

Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics

Completed·CCalo Psychiatric Center·Phase 1·NCT03730857·111 enrolled

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

Completed·HHarvard Medical School (HMS and HSDM)·Phase 4·NCT00169065·38 enrolled

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

Completed·OOrganon and Co·Phase 3·NCT00212836·481 enrolled

Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00103571·600 enrolled

Antipsychotic Response in Schizophrenia

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00018668

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT00615433·478 enrolled

A Study of ALKS 3831 in Adults With Schizophrenia

Completed·AAlkermes, Inc.·Phase 2·NCT01903837·347 enrolled

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

Completed·UUniversity of North Carolina, Chapel Hill·N/A·NCT01234454·34 enrolled

Sertindole in Asian Patients With Schizophrenia

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT00864045·394 enrolled

Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT00759460·250 enrolled

Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia

Completed·—·Phase 4·NCT01164059·149 enrolled

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

Completed·NNorthwell Health·Phase 4·NCT00330863·357 enrolled

Polypharmacy in Clozapine-resistant Schizophrenia

Completed·—·Phase 4·NCT00918021·30 enrolled

SB-773812 Administered In Adults With Schizophrenia

Completed· GSK logo

GSK·Phase 2·NCT00259870·338 enrolled

Treatment for First-Episode Schizophrenia

Completed·NNorthwell Health·Phase 4·NCT00000374·125 enrolled

Standard Comprehensive Intervention to Treat First-episode Schizophrenia

Unknown status·PPeking University·N/A·NCT01057849·600 enrolled

Treating Drug-Resistant Childhood Schizophrenia

Completed·NNorthwell Health·Phase 4·NCT00048828·41 enrolled

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

Completed·AAlkermes, Inc.·Phase 3·NCT02634346·403 enrolled

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)

Completed·OOrganon and Co·Phase 3·NCT00145496·468 enrolled

Characterizing Response to Antipsychotics in Schizophrenia

Unknown status·TThe Royal Ottawa Mental Health Centre··NCT06159322·40 enrolled

An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00728195·498 enrolled

Switching Medication to Treat Schizophrenia

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT00044655·219 enrolled

Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia

Completed·—·N/A·NCT02918825·100 enrolled

5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia

Completed·KKunming Medical University·Phase 4·NCT02435654·128 enrolled

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

Completed·DDenovo Biopharma LLC·Phase 2·NCT00149292·195 enrolled

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00645099·462 enrolled

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00051298·107 enrolled

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01157351·450 enrolled

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Completed· Roche logo

Roche·Phase 2·NCT01234779·301 enrolled

Olanzapine18 trials

Olanzapine in OUD Patients

Withdrawn·UUniversity of Pennsylvania·Phase 2·NCT05179772

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00402324·202 enrolled

IM Olanzapine Versus Haloperidol or Midazolam

Terminated·TThe University of Hong Kong·Phase 4·NCT02380118·167 enrolled

Show 15 more trials

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00303602·149 enrolled

Intranasal Insulin and Olanzapine Study in Healthy Volunteers

Unknown status·CCentre for Addiction and Mental Health·Phase 1·NCT03741478·64 enrolled

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed Condition

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT01996501

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT01996488

Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features

Completed·MMelbourne Health·Phase 4·NCT00202293·83 enrolled

Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

Completed·NNew York State Psychiatric Institute·Phase 4·NCT01920802·31 enrolled

Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00191997·180 enrolled

9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00143182·504 enrolled

Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis

Terminated·KKarin Jordan·Phase 2·NCT01148264·23 enrolled

Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Completed·IInstituto do Cancer do Estado de São Paulo·Phase 2/3·NCT03631004·100 enrolled

Ziprasidone And Olanzapine's Outcomes In Mania

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00329108·29 enrolled

Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00190892·120 enrolled

3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

Completed·OOrganon and Co·Phase 3·NCT00159796·489 enrolled

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)

Completed·OOrganon and Co·Phase 3·NCT00265343·306 enrolled

Metabolic Effects of Olanzapine in Healthy Males

Completed·SState University of New York at Buffalo·N/A·NCT01496183·24 enrolled

Nausea and vomiting10 trials

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Completed·UUniversity of Rochester NCORP Research Base·Phase 3·NCT03367572·1,363 enrolled

A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron

Not yet recruiting·HHenan Cancer Hospital·N/A·NCT07442890·238 enrolled

"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"

Completed·—·Phase 3·NCT03219710·240 enrolled

Show 7 more trials

Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02290470·81 enrolled

Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

Completed·IInstituto Brasileiro de Controle do Cancer·Phase 2·NCT04669132·50 enrolled

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT03578081·690 enrolled

Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care

Unknown status·KKhon Kaen University·Phase 2·NCT03679182·15 enrolled

Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 3·NCT05346731·210 enrolled

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 3·NCT04503668·62 enrolled

Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer

Unknown status·ZZunyi Medical College·Phase 4·NCT03571126·156 enrolled

Bipolar I Disorder7 trials

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00034580·326 enrolled

Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00618748·101 enrolled

Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00266630·139 enrolled

Show 4 more trials

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

Completed·AAlkermes, Inc.·Phase 3·NCT03187769·426 enrolled

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00490971·768 enrolled

Olanzapine Treatment of Patients With Bipolar I Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00510146·514 enrolled

Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00113594·100 enrolled

Schizoaffective Disorder7 trials

A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00236379·59 enrolled

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Completed· Teva logo

Teva·Phase 1·NCT06319170·106 enrolled

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

Completed·NNational Institute of Mental Health (NIMH)·Phase 4·NCT00423878·215 enrolled

Show 4 more trials

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)

Completed·OOrganon and Co·Phase 3·NCT00212771·440 enrolled

A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Unknown status·SShalvata Mental Health Center·N/A·NCT01389908·2 enrolled

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00090012·340 enrolled

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00100776·600 enrolled

60 more indications

Bipolar Disorder7 trials

A Study of Olanzapine in Participants With Bipolar Disorder.

Recruiting· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd··NCT07263191·3,000 enrolled

Study in Adolescents With Schizophrenia or Bipolar Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00982020·203 enrolled

Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 4·NCT02562287·54 enrolled

Show 4 more trials

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated·UUniversity of New Mexico··NCT02893371·1,037,352 enrolled

Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder

Completed·TTri-Service General Hospital·Phase 4·NCT01864551·60 enrolled

40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

Completed·OOrganon and Co·Phase 3·NCT00159783·218 enrolled

Treatment and Outcome of Early Onset Bipolar Disorder

Completed·NNorthwell Health·Phase 4·NCT00048802·40 enrolled

Anorexia Nervosa6 trials

Olanzapine in the Treatment of Anorexia Nervosa

Completed·NNorthwell Health·Phase 4·NCT00592930·20 enrolled

Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00685334·22 enrolled

Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents

Terminated·—·Phase 3·NCT01184443·38 enrolled

Show 3 more trials

Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

Completed·NNew York State Psychiatric Institute·N/A·NCT01170117·152 enrolled

Olanzapine in the Treatment of Patients With Anorexia Nervosa

Completed·OOttawa Hospital Research Institute·Phase 2·NCT00260962·34 enrolled

Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

Completed·NNew York State Psychiatric Institute·Phase 2·NCT00692185·23 enrolled

Antipsychotics5 trials

Effects of Antipsychotics on Brain Insulin Action in Females

Recruiting·CCentre for Addiction and Mental Health·N/A·NCT06251635·15 enrolled

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Completed·TTechnical University of Munich·Phase 4·NCT02307396·21 enrolled

Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting

Completed·UUniversity of Bergen·Phase 4·NCT00932529·226 enrolled

Show 2 more trials

Energy Homeostasis Under Treatment With Atypical Antipsychotics

Completed·—·Phase 4·NCT00148564·40 enrolled

Side Effects of Newer Antipsychotics in Older Adults

Completed·VVeterans Medical Research Foundation·Phase 4·NCT00245206·406 enrolled

Vomiting4 trials

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

Withdrawn·MMayo Clinic·Phase 3·NCT05403580

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

Recruiting·—·Phase 3·NCT06588413·172 enrolled

Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy

Not yet recruiting·SShanghai Children's Medical Center·Phase 3·NCT07035821·100 enrolled

Show 1 more trial

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

Completed·UUniversity of Alabama at Birmingham·Phase 2/3·NCT03137121·30 enrolled

Chemotherapy-induced nausea and vomiting4 trials

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT02116530·401 enrolled

Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 3·NCT04232423·90 enrolled

Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study

Completed·TThe Hospital for Sick Children·Phase 2·NCT02129478·15 enrolled

Show 1 more trial

Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 3·NCT02484911·120 enrolled

Efficacy and Safety4 trials

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

Terminated·—·Phase 2·NCT02088060·150 enrolled

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)

Completed·OOrganon and Co·Phase 3·NCT00151424·277 enrolled

Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)

Completed·OOrganon and Co·Phase 3·NCT00156091·260 enrolled

Show 1 more trial

An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC

Not yet recruiting·SShanghai 6th People's Hospital·Phase 4·NCT07482891·200 enrolled

Chemotherapy3 trials

Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy

Recruiting·MMahidol University·Phase 3·NCT06850454·140 enrolled

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Withdrawn·CCostantine Albany·Phase 2·NCT03960151

A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy

Unknown status·KKorean South West Oncology Group·Phase 2·NCT02400866·58 enrolled

Dexamethasone3 trials

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

Recruiting·—·Phase 3·NCT07413809·92 enrolled

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Not yet recruiting·FFudan University·Phase 3·NCT06331520·627 enrolled

Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN

Unknown status·HHee Jun Kim·N/A·NCT02970643·48 enrolled

Agitation3 trials

Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

Completed·HHennepin Healthcare Research Institute··NCT03211897·737 enrolled

Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

Completed·UUniversity of Sao Paulo·N/A·NCT01485692·120 enrolled

A Study of Olanzapine in Patients With Acute Agitation

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05803642·318 enrolled

Delirium3 trials

Comparing Haloperidol and Olanzapine in Treating Terminal Delirium

Unknown status·HHCA Hospice Care·Phase 2·NCT04750395·80 enrolled

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

Completed·MM.D. Anderson Cancer Center·N/A·NCT00512291·25 enrolled

Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

Completed·TThe New England Baptist Hospital·N/A·NCT00699946·495 enrolled

Metabolism3 trials

Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism

Completed·—·N/A·NCT01160991·10 enrolled

Glucose and Lipid Metabolism on Antipsychotic Medication

Completed·WWashington University School of Medicine·N/A·NCT00515723·96 enrolled

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

Completed·NNathan Kline Institute for Psychiatric Research·Phase 4·NCT00287820·46 enrolled

Psychosis3 trials

Bergen Psychosis Project 2 - The Best Intro Study

Completed·HHaukeland University Hospital·Phase 4·NCT01446328·151 enrolled

Antipsychotic to Treat Psychosis Syndrome

Unknown status·—·N/A·NCT02137616·300 enrolled

A Comparative Study of New Medications for Psychosis in Adolescents

Completed·UUniversity of Minnesota·N/A·NCT00222495·30 enrolled

Borderline personality disorder2 trials

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

Completed·UUniversity of Minnesota·N/A·NCT00275301·19 enrolled

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00088036·450 enrolled

Weight loss2 trials

Olanzapine in Patients With Advanced Cancer and Weight Loss

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00489593·57 enrolled

Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer

Enrolling by invitation·EEnglewood Hospital and Medical Center·Phase 2·NCT05170919·170 enrolled

Tardive Dyskinesia2 trials

Tardive Dyskinesia and Cognitive Function

Completed·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT00926965·80 enrolled

Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia

Completed·TTaoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan·Phase 4·NCT00621998·60 enrolled

Treatment Resistant Depression2 trials

A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

Terminated· Eli Lilly logo

Eli Lilly·Phase 3·NCT01687478·176 enrolled

Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression

Completed·SSunnybrook Health Sciences Centre·Phase 1/2·NCT01282632·42 enrolled

TIPS2 trials

"Extended" (Alternate Day) Antipsychotic Dosing

Recruiting·CCentre for Addiction and Mental Health·Phase 4·NCT04478838·120 enrolled

Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction

Completed·MMichael Rickels·Phase 1·NCT02447835·15 enrolled

Cognitive impairment2 trials

Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome

Suspended·SShanghai Mental Health Center·Phase 2·NCT04518319·120 enrolled

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Completed· Astellas logo

Astellas·Phase 2·NCT03557931·233 enrolled

Safety and Efficacy2 trials

Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine

Terminated·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT00194064·18 enrolled

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00401973·199 enrolled

Weight Gain2 trials

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Completed·LLindner Center of HOPE·Phase 3·NCT00363376·42 enrolled

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Completed·CCorcept Therapeutics·Phase 1·NCT03877562·96 enrolled

Treatment2 trials

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Completed·DDenovo Biopharma LLC·Phase 2·NCT00845026·261 enrolled

The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

Unknown status·SShanxi Medical University·Phase 1/2·NCT02650102·200 enrolled

Depression2 trials

Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)

Completed·TTadashi Hasegawa·Phase 4·NCT02287259·50 enrolled

Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00485771·403 enrolled

Interaction2 trials

Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)

Completed·RRadboud University Medical Center·Phase 1·NCT00977301·24 enrolled

Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

Completed·—·Phase 1·NCT02051387·74 enrolled

Effectiveness1 trial

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

Terminated·MMassachusetts General Hospital·N/A·NCT00183612·68 enrolled

Trichotillomania1 trial

Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

Completed·HHamilton Health Sciences Corporation·Phase 4·NCT00182507·34 enrolled

Acceptability1 trial

Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

Unknown status·GGuiyun Xu·Phase 4·NCT01893229·120 enrolled

Pediatric1 trial

Pediatric Oncology Nutrition Intervention Trial

Completed·CCorey Hawes·Phase 2/3·NCT06175273·19 enrolled

Anorexia1 trial

Olanzapine for Cancer Related Anorexia-cachexia Syndrome

Recruiting·MMahidol University·Phase 3·NCT06517199·138 enrolled

Lung Cancer1 trial

Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

Recruiting·QQinghai Red Cross Hospital·Phase 3·NCT06338683·230 enrolled

Insulin resistance1 trial

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

Completed·WWayne State University·Phase 1·NCT02708394·31 enrolled

Cardiac Arrest1 trial

The Danish Out-of-Hospital Cardiac Arrest Study

Recruiting·CChristian Hassager·Phase 3·NCT05895838·1,000 enrolled

Cancer Pain1 trial

Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain

Withdrawn·MMayo Clinic·N/A·NCT00737191

HNSCC1 trial

The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT05202275·43 enrolled

Nausea1 trial

Olanzapine for Nausea After Surgery

Completed·JJaime B Hyman·Phase 2·NCT02755116·180 enrolled

Cognitive Change1 trial

An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients

Completed·QQueen's University·Phase 4·NCT00520507·27 enrolled

Medication1 trial

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02462473·9 enrolled

Lip1 trial

Detoxification From the Lipid Tract

Completed·PPachankis, Yang I., M.D.·Phase 4·NCT06357104·1 enrolled

Aggression1 trial

Clozapine and Olanzapine Treatment of Aggression

Completed·NNathan Kline Institute for Psychiatric Research·N/A·NCT01123408·110 enrolled

Cognition1 trial

Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)

Terminated·UUniversity of Aarhus·N/A·NCT00885690·11 enrolled

Cardiovascular1 trial

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

Completed· Pfizer logo

Pfizer·Phase 4·NCT00418171·18,239 enrolled

Drug Monitoring1 trial

Therapeutic Drug Monitoring in Child and Adolescent Psychiatry

Completed·MMedical University of Vienna··NCT01057329·200 enrolled

Mood Disorder1 trial

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177567·60 enrolled

Antidepressants1 trial

Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD

Completed·SSykehuset Innlandet HF·Phase 4·NCT00433121·24 enrolled

Developmental Delay1 trial

Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00065273·50 enrolled

Autism1 trial

Long-Term Olanzapine Treatment in Children With Autism

Completed·—·Phase 2/3·NCT00183404·32 enrolled

Immunotherapy1 trial

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

Not yet recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 2·NCT06554613·156 enrolled

Amyotrophic Lateral Sclerosis1 trial

Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)

Completed·—·Phase 2/3·NCT00876772·40 enrolled

Insulin Sensitivity1 trial

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

Completed·VVeterans Medical Research Foundation·Phase 4·NCT00895921·30 enrolled

Major Depressive Disorder1 trial

A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder

Completed·UUniversity Health Network, Toronto·Phase 4·NCT00188942·42 enrolled

Observational Study1 trial

An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.

Completed· Eli Lilly logo

Eli Lilly··NCT00510211·1,131 enrolled

Movement Disorder1 trial

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

Completed·UUniversity of California, San Diego·Phase 1·NCT00255879·250 enrolled

Maintenance Treatment1 trial

Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

Completed·UUniversity of British Columbia·Phase 3·NCT01977300·159 enrolled

Chronic1 trial

Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans

Completed·LLeiden University Medical Center·N/A·NCT00625170·11 enrolled

Major Depression1 trial

Optimal Duration of Olanzapine Add-on Therapy in Major Depression

Withdrawn·—·Phase 3·NCT00568672

Combination Therapy1 trial

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Terminated·AAbbott·Phase 4·NCT00071253·180 enrolled

Monotherapy1 trial

Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression

Completed·—·Phase 4·NCT01303601·68 enrolled

AIN1 trial

Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy

Terminated·UUniversity of Jena·Phase 4·NCT00419653·19 enrolled

Alzheimer's Disease1 trial

CATIE-Alzheimer's Disease Trial

Completed·NNational Institute of Mental Health (NIMH)·N/A·NCT00015548·450 enrolled

Tic Disorder1 trial

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

Unknown status·—·Phase 4·NCT03857581·100 enrolled

Unspecified1 trial

A First In Human Study Of PF-00184562 In Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT00150215·18 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 30, 1996

ZYPREXA

NDA NDA020592

Sep 30, 1996

ZYPREXA

NDA NDA020592

Apr 18, 1997

ZYPREXA

NDA NDA020592

Sep 9, 1997

ZYPREXA

NDA NDA020592

Dec 4, 1997

ZYPREXA

NDA NDA020592

Mar 23, 1998

ZYPREXA

NDA NDA020592

Jan 11, 1999

ZYPREXA

NDA NDA020592

Mar 17, 2000

ZYPREXA

NDA NDA020592

Apr 6, 2000

ZYPREXA ZYDIS

NDA NDA021086

Apr 6, 2000

ZYPREXA ZYDIS

NDA NDA021086

Nov 9, 2000

ZYPREXA

NDA NDA020592

Mar 13, 2001

ZYPREXA

NDA NDA020592

Oct 24, 2001

ZYPREXA ZYDIS

NDA NDA021086

Jan 22, 2002

ZYPREXA

NDA NDA020592

Jul 10, 2003

ZYPREXA

NDA NDA020592

Jan 14, 2004

ZYPREXA

NDA NDA020592

Mar 29, 2004

ZYPREXA

NDA NDA021253

Mar 29, 2004

ZYPREXA

NDA NDA021253

Jun 29, 2005

ZYPREXA

NDA NDA020592

Aug 3, 2005

ZYPREXA

NDA NDA020592

Sep 13, 2005

ZYPREXA

NDA NDA020592

Sep 13, 2005

ZYPREXA

NDA NDA021253

Sep 13, 2005

ZYPREXA ZYDIS

NDA NDA021086

Feb 16, 2006

ZYPREXA

NDA NDA020592

Feb 16, 2006

ZYPREXA

NDA NDA021253

Feb 16, 2006

ZYPREXA

NDA NDA021253

Feb 16, 2006

ZYPREXA ZYDIS

NDA NDA021086

Feb 16, 2006

ZYPREXA ZYDIS

NDA NDA021086

Feb 16, 2006

ZYPREXA

NDA NDA020592

Feb 23, 2006

ZYPREXA

NDA NDA021253

Feb 23, 2006

ZYPREXA

NDA NDA020592

Feb 23, 2006

ZYPREXA ZYDIS

NDA NDA021086

Aug 25, 2006

ZYPREXA ZYDIS

NDA NDA021086

Aug 25, 2006

ZYPREXA

NDA NDA020592

Aug 25, 2006

ZYPREXA

NDA NDA021253

Nov 29, 2006

ZYPREXA

NDA NDA020592

Nov 29, 2006

ZYPREXA

NDA NDA021253

Nov 29, 2006

ZYPREXA ZYDIS

NDA NDA021086

Jul 6, 2007

ZYPREXA

NDA NDA021253

Jul 6, 2007

ZYPREXA

NDA NDA020592

Jul 6, 2007

ZYPREXA

NDA NDA020592

Jul 6, 2007

ZYPREXA ZYDIS

NDA NDA021086

Jul 6, 2007

ZYPREXA ZYDIS

NDA NDA021086

Aug 14, 2008

ZYPREXA

NDA NDA020592

Aug 14, 2008

ZYPREXA ZYDIS

NDA NDA021086

Aug 14, 2008

ZYPREXA

NDA NDA021253

Mar 19, 2009

ZYPREXA

NDA NDA020592

Mar 19, 2009

ZYPREXA ZYDIS

NDA NDA021086

Aug 31, 2009

ZYPREXA

NDA NDA020592

Aug 31, 2009

ZYPREXA

NDA NDA021253

Aug 31, 2009

ZYPREXA ZYDIS

NDA NDA021086

Dec 4, 2009

ZYPREXA

NDA NDA020592

Dec 4, 2009

ZYPREXA

NDA NDA020592

Dec 11, 2009

ZYPREXA RELPREVV

NDA NDA022173

Dec 11, 2009

ZYPREXA RELPREVV

NDA NDA022173

Jan 27, 2010

ZYPREXA

NDA NDA020592

Jan 27, 2010

ZYPREXA ZYDIS

NDA NDA021086

Jan 27, 2010

ZYPREXA

NDA NDA021253

Apr 27, 2010

ZYPREXA RELPREVV

NDA NDA022173

May 27, 2010

ZYPREXA

NDA NDA021253

May 27, 2010

ZYPREXA RELPREVV

NDA NDA022173

May 27, 2010

ZYPREXA

NDA NDA020592

May 27, 2010

ZYPREXA RELPREVV

NDA NDA022173

May 27, 2010

ZYPREXA

NDA NDA021253

May 27, 2010

ZYPREXA

NDA NDA020592

May 27, 2010

ZYPREXA ZYDIS

NDA NDA021086

May 27, 2010

ZYPREXA ZYDIS

NDA NDA021086

Jul 8, 2010

ZYPREXA RELPREVV

NDA NDA022173

Dec 1, 2010

ZYPREXA ZYDIS

NDA NDA021086

Dec 1, 2010

ZYPREXA RELPREVV

NDA NDA022173

Dec 1, 2010

ZYPREXA

NDA NDA020592

Dec 1, 2010

ZYPREXA

NDA NDA021253

Jun 21, 2011

ZYPREXA ZYDIS

NDA NDA021086

Jun 21, 2011

ZYPREXA

NDA NDA020592

Jun 21, 2011

ZYPREXA

NDA NDA020592

Jun 21, 2011

ZYPREXA ZYDIS

NDA NDA021086

Aug 3, 2012

ZYPREXA RELPREVV

NDA NDA022173

Aug 3, 2012

ZYPREXA RELPREVV

NDA NDA022173

Aug 3, 2012

ZYPREXA RELPREVV

NDA NDA022173

Mar 27, 2013

ZYPREXA RELPREVV

NDA NDA022173

Jul 26, 2013

ZYPREXA ZYDIS

NDA NDA021086

Jul 26, 2013

ZYPREXA

NDA NDA020592

Oct 21, 2013

ZYPREXA

NDA NDA020592

Oct 25, 2013

ZYPREXA

NDA NDA020592

Feb 18, 2014

ZYPREXA RELPREVV

NDA NDA022173

Aug 11, 2014

ZYPREXA

NDA NDA021253

Sep 30, 2014

ZYPREXA

NDA NDA021253

Oct 30, 2014

ZYPREXA RELPREVV

NDA NDA022173

Dec 19, 2014

ZYPREXA

NDA NDA020592

Dec 19, 2014

ZYPREXA ZYDIS

NDA NDA021086

Dec 19, 2014

ZYPREXA RELPREVV

NDA NDA022173

Dec 19, 2014

ZYPREXA

NDA NDA021253

Jul 23, 2015

ZYPREXA RELPREVV

NDA NDA022173

Jul 23, 2015

ZYPREXA

NDA NDA020592

Jul 23, 2015

ZYPREXA

NDA NDA021253

Jul 23, 2015

ZYPREXA ZYDIS

NDA NDA021086

Sep 17, 2015

ZYPREXA RELPREVV

NDA NDA022173

Dec 23, 2015

ZYPREXA RELPREVV

NDA NDA022173

Oct 6, 2016

ZYPREXA RELPREVV

NDA NDA022173

Oct 6, 2016

ZYPREXA

NDA NDA021253

Oct 6, 2016

ZYPREXA

NDA NDA020592

Oct 6, 2016

ZYPREXA ZYDIS

NDA NDA021086

Oct 27, 2016

ZYPREXA

NDA NDA021253

Feb 23, 2017

ZYPREXA ZYDIS

NDA NDA021086

Feb 23, 2017

ZYPREXA

NDA NDA020592

Feb 23, 2017

ZYPREXA

NDA NDA021253

Feb 23, 2017

ZYPREXA

NDA NDA020592

Feb 23, 2017

ZYPREXA

NDA NDA021253

Feb 23, 2017

ZYPREXA RELPREVV

NDA NDA022173

Feb 23, 2017

ZYPREXA RELPREVV

NDA NDA022173

Feb 23, 2017

ZYPREXA ZYDIS

NDA NDA021086

Nov 30, 2017

ZYPREXA RELPREVV

NDA NDA022173

Mar 27, 2018

ZYPREXA ZYDIS

NDA NDA021086

Mar 27, 2018

ZYPREXA RELPREVV

NDA NDA022173

Mar 27, 2018

ZYPREXA

NDA NDA020592

Mar 27, 2018

ZYPREXA

NDA NDA021253

Apr 11, 2019

ZYPREXA RELPREVV

NDA NDA022173

Oct 22, 2019

ZYPREXA ZYDIS

NDA NDA021086

Oct 22, 2019

ZYPREXA

NDA NDA021253

Oct 22, 2019

ZYPREXA

NDA NDA020592

Oct 22, 2019

ZYPREXA RELPREVV

NDA NDA022173

Apr 21, 2020

ZYPREXA

NDA NDA021253

Apr 21, 2020

ZYPREXA RELPREVV

NDA NDA022173

Apr 21, 2020

ZYPREXA

NDA NDA020592

Apr 21, 2020

ZYPREXA ZYDIS

NDA NDA021086

Apr 22, 2020

ZYPREXA RELPREVV

NDA NDA022173

Apr 23, 2020

ZYPREXA ZYDIS

NDA NDA021086

Apr 23, 2020

ZYPREXA

NDA NDA020592

Apr 23, 2020

ZYPREXA RELPREVV

NDA NDA022173

Apr 23, 2020

ZYPREXA

NDA NDA021253

Jan 13, 2021

ZYPREXA RELPREVV

NDA NDA022173

Apr 28, 2021

ZYPREXA RELPREVV

NDA NDA022173

Jan 22, 2025

ZYPREXA ZYDIS

NDA NDA021086

Jan 22, 2025

ZYPREXA RELPREVV

NDA NDA022173

Jan 22, 2025

ZYPREXA

NDA NDA021253

Jan 22, 2025

ZYPREXA

NDA NDA020592

Jan 30, 2026

ZYPREXA

NDA NDA021253

Jan 30, 2026

ZYPREXA ZYDIS

NDA NDA021086

Jan 30, 2026

ZYPREXA

NDA NDA020592

Jan 30, 2026

ZYPREXA RELPREVV

NDA NDA022173

May 7, 2026

ZYPREXA RELPREVV

NDA NDA022173

May 7, 2026

ZYPREXA RELPREVV

NDA NDA022173

Sources

References

[1]
ClinicalTrials.gov — 316 trial records for olanzapine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Zyprexa drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — olanzapine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for olanzapine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022173). U.S. Food & Drug Administration.
[6]
SEC EDGAR — MODAG GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: D2-Like Dopamine Receptor Antagonist; Serotonin 2c (5-Ht2c) Receptor Antagonist; Serotonin 2a (5-Ht2a) Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: MMODAG GmbH

Zyprexa

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Schizophrenia51 trials

Olanzapine18 trials

Nausea and vomiting10 trials

Bipolar I Disorder7 trials

Schizoaffective Disorder7 trials

Bipolar Disorder7 trials

Anorexia Nervosa6 trials

Antipsychotics5 trials

Vomiting4 trials

Chemotherapy-induced nausea and vomiting4 trials

Efficacy and Safety4 trials

Chemotherapy3 trials

Dexamethasone3 trials

Agitation3 trials

Delirium3 trials

Metabolism3 trials

Psychosis3 trials

Borderline personality disorder2 trials

Weight loss2 trials

Tardive Dyskinesia2 trials

Treatment Resistant Depression2 trials

TIPS2 trials

Cognitive impairment2 trials

Safety and Efficacy2 trials

Weight Gain2 trials

Treatment2 trials

Depression2 trials

Interaction2 trials

Effectiveness1 trial

Trichotillomania1 trial

Acceptability1 trial

Pediatric1 trial

Anorexia1 trial

Lung Cancer1 trial

Insulin resistance1 trial

Cardiac Arrest1 trial

Cancer Pain1 trial

HNSCC1 trial

Nausea1 trial

Cognitive Change1 trial

Medication1 trial

Lip1 trial

Aggression1 trial

Cognition1 trial

Cardiovascular1 trial

Drug Monitoring1 trial

Mood Disorder1 trial

Antidepressants1 trial

Developmental Delay1 trial

Autism1 trial

Immunotherapy1 trial

Amyotrophic Lateral Sclerosis1 trial

Insulin Sensitivity1 trial

Major Depressive Disorder1 trial

Observational Study1 trial

Movement Disorder1 trial

Maintenance Treatment1 trial

Chronic1 trial

Major Depression1 trial

Combination Therapy1 trial

Monotherapy1 trial

AIN1 trial

Alzheimer's Disease1 trial

Tic Disorder1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News